Single-Domain EGFR Binding Molecule Targets Membrane-Proximal Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-EGFR therapies face challenges due to high mutation rates and drug resistance in EGFR, necessitating the development of a novel anti-EGFR binding molecule with high specificity, blocking activity, and reduced drug burden.
Innovation Solution
A human epidermal growth factor receptor binding molecule comprising a single domain antibody with specific CDR sequences (SEQ ID NOs: 1, 2, and 3) targeting the membrane proximal regions III or IV of EGFR, offering high affinity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional EGFR mAbs (cetuximab, panitumumab, etc.) are used for tumor therapy, then EGFR targeting capability is achieved, but drug resistance and mutation tolerance are poor due to high mutation rates in EGFR extracellular segment
Solution Approach 1:
The patent divides the traditional full antibody structure into a single-domain antibody (VHH) segment that retains the essential antigen-binding capability while eliminating unnecessary structural complexity. This segmentation allows the antibody to focus on binding conserved regions of EGFR, improving mutation tolerance while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates a simplified copy of the antibody's essential function using only the VHH domain, which contains the CDR regions necessary for antigen binding. This copied functional element binds to conserved epitopes on EGFR, providing resistance to mutations that affect traditional full-length antibodies.
2Reliability
If traditional full-length antibodies are used, then high affinity binding to EGFR is achieved, but production complexity and cost are high
Solution Approach 1:
The patent extracts only the essential VHH domain from the full antibody structure, removing the heavy and light chain constant regions that complicate production. This extracted VHH segment retains high binding affinity through its CDR regions while being much simpler to produce recombinantly in various expression systems.
Solution Approach 2:
The single-domain antibody structure serves as a simplified, cost-effective alternative to full-length antibodies. It can be produced more cheaply in bacterial or yeast expression systems without requiring complex mammalian cell culture infrastructure, making it an economical therapeutic option.
3Measurement precision
If nanobodies with small binding epitope are used, then specificity and penetration capability are improved, but research on membrane proximal region targeting is insufficient
Solution Approach 1:
The patent optimizes the CDR regions of the VHH domain to specifically recognize and bind to the membrane proximal regions (III or IV) of EGFR. This local optimization of binding specificity allows the nanobody to target previously underexplored regions of the receptor, enhancing both specificity and therapeutic potential.
Data Source
AI summary
Provided in the present invention are a human epidermal growth factor receptor binding molecule and the use thereof. The human epidermal growth factor receptor binding molecule of the present invention contains a single domain antibody, which is against the human epidermal growth factor receptor. A complementary determining region (CDR) of the single domain antibody comprises CDR1, as represented by SEQ ID NO: 1, CDR2, as represented by SEQ ID NO: 2, and CDR3, as represented by SEQ ID NO: 3. Also provided in the present invention are a polynucleotide encoding the binding molecule, a nucleic acid construct containing same, and a corresponding phage, host cell, pharmaceutical composition, production method and non-diagnostic method, and the corresponding use.